For example, the expression level of cyclin D1 (CCND1) was shown to be significantly reduced in patients with head and neck squamous cell carcinoma (HNSCC) following nivolumab treatment [77]. This evidence concerns the gene CCND1 and head and neck squamous cell carcinoma.